FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013062810> ?p ?o ?g. }

• W3013062810 endingPage "147" @default.
• W3013062810 startingPage "139" @default.
• W3013062810 abstract "Background & AimsWe investigated the effects of inducing deep remission in patients with early Crohn’s disease (CD).MethodsWe collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1–0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05–6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period.ResultsMajor adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07–0.31) was significantly associated with a lower risk of major adverse outcome.ConclusionsIn an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy. We investigated the effects of inducing deep remission in patients with early Crohn’s disease (CD). We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1–0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05–6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07–0.31) was significantly associated with a lower risk of major adverse outcome. In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy." @default.
• W3013062810 created "2020-04-03" @default.
• W3013062810 creator A5008149243 @default.
• W3013062810 creator A5009680823 @default.
• W3013062810 creator A5009906875 @default.
• W3013062810 creator A5011546745 @default.
• W3013062810 creator A5013058329 @default.
• W3013062810 creator A5015981601 @default.
• W3013062810 creator A5019960092 @default.
• W3013062810 creator A5020196494 @default.
• W3013062810 creator A5021791508 @default.
• W3013062810 creator A5022022076 @default.
• W3013062810 creator A5029428855 @default.
• W3013062810 creator A5033087694 @default.
• W3013062810 creator A5034722460 @default.
• W3013062810 creator A5038889616 @default.
• W3013062810 creator A5039504054 @default.
• W3013062810 creator A5041965034 @default.
• W3013062810 creator A5042884495 @default.
• W3013062810 creator A5046232245 @default.
• W3013062810 creator A5047563454 @default.
• W3013062810 creator A5049988663 @default.
• W3013062810 creator A5054322001 @default.
• W3013062810 creator A5054590261 @default.
• W3013062810 creator A5054937736 @default.
• W3013062810 creator A5055204929 @default.
• W3013062810 creator A5056474210 @default.
• W3013062810 creator A5056979580 @default.
• W3013062810 creator A5057448803 @default.
• W3013062810 creator A5057899912 @default.
• W3013062810 creator A5058012401 @default.
• W3013062810 creator A5058934291 @default.
• W3013062810 creator A5059435501 @default.
• W3013062810 creator A5059585778 @default.
• W3013062810 creator A5064276019 @default.
• W3013062810 creator A5065307928 @default.
• W3013062810 creator A5068268866 @default.
• W3013062810 creator A5080041744 @default.
• W3013062810 creator A5082614934 @default.
• W3013062810 creator A5084884365 @default.
• W3013062810 creator A5089864044 @default.
• W3013062810 date "2020-07-01" @default.
• W3013062810 modified "2023-10-18" @default.
• W3013062810 title "Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease" @default.
• W3013062810 cites W1547943993 @default.
• W3013062810 cites W1942766989 @default.
• W3013062810 cites W2017149988 @default.
• W3013062810 cites W2024269361 @default.
• W3013062810 cites W2035863637 @default.
• W3013062810 cites W2056586250 @default.
• W3013062810 cites W2149170290 @default.
• W3013062810 cites W2168056382 @default.
• W3013062810 cites W2168148602 @default.
• W3013062810 cites W2177407638 @default.
• W3013062810 cites W2336100848 @default.
• W3013062810 cites W2605973049 @default.
• W3013062810 cites W2765952171 @default.
• W3013062810 cites W2766230215 @default.
• W3013062810 cites W2785248466 @default.
• W3013062810 cites W2914644677 @default.
• W3013062810 cites W2926897045 @default.
• W3013062810 doi "https://doi.org/10.1053/j.gastro.2020.03.039" @default.
• W3013062810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7751802" @default.
• W3013062810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32224129" @default.
• W3013062810 hasPublicationYear "2020" @default.
• W3013062810 type Work @default.
• W3013062810 sameAs 3013062810 @default.
• W3013062810 citedByCount "112" @default.
• W3013062810 countsByYear W30130628102020 @default.
• W3013062810 countsByYear W30130628102021 @default.
• W3013062810 countsByYear W30130628102022 @default.
• W3013062810 countsByYear W30130628102023 @default.
• W3013062810 crossrefType "journal-article" @default.
• W3013062810 hasAuthorship W3013062810A5008149243 @default.
• W3013062810 hasAuthorship W3013062810A5009680823 @default.
• W3013062810 hasAuthorship W3013062810A5009906875 @default.
• W3013062810 hasAuthorship W3013062810A5011546745 @default.
• W3013062810 hasAuthorship W3013062810A5013058329 @default.
• W3013062810 hasAuthorship W3013062810A5015981601 @default.
• W3013062810 hasAuthorship W3013062810A5019960092 @default.
• W3013062810 hasAuthorship W3013062810A5020196494 @default.
• W3013062810 hasAuthorship W3013062810A5021791508 @default.
• W3013062810 hasAuthorship W3013062810A5022022076 @default.
• W3013062810 hasAuthorship W3013062810A5029428855 @default.
• W3013062810 hasAuthorship W3013062810A5033087694 @default.
• W3013062810 hasAuthorship W3013062810A5034722460 @default.
• W3013062810 hasAuthorship W3013062810A5038889616 @default.
• W3013062810 hasAuthorship W3013062810A5039504054 @default.
• W3013062810 hasAuthorship W3013062810A5041965034 @default.
• W3013062810 hasAuthorship W3013062810A5042884495 @default.
• W3013062810 hasAuthorship W3013062810A5046232245 @default.
• W3013062810 hasAuthorship W3013062810A5047563454 @default.
• W3013062810 hasAuthorship W3013062810A5049988663 @default.
• W3013062810 hasAuthorship W3013062810A5054322001 @default.
• W3013062810 hasAuthorship W3013062810A5054590261 @default.
• W3013062810 hasAuthorship W3013062810A5054937736 @default.
• W3013062810 hasAuthorship W3013062810A5055204929 @default.
• W3013062810 hasAuthorship W3013062810A5056474210 @default.

• next